151 related articles for article (PubMed ID: 35267415)
41. Model based patient pre-selection for intensity-modulated proton therapy (IMPT) using automated treatment planning and machine learning.
Kouwenberg J; Penninkhof J; Habraken S; Zindler J; Hoogeman M; Heijmen B
Radiother Oncol; 2021 May; 158():224-229. PubMed ID: 33667584
[TBL] [Abstract][Full Text] [Related]
42. Intensity Modulated Proton Beam Therapy versus Volumetric Modulated Arc Therapy for Patients with Nasopharyngeal Cancer: A Propensity Score-Matched Study.
Chou YC; Fan KH; Lin CY; Hung TM; Huang BS; Chang KP; Kang CJ; Huang SF; Chang PH; Hsu CL; Wang HM; Hsieh JC; Cheng AJ; Chang JT
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298769
[TBL] [Abstract][Full Text] [Related]
43. Intensity-modulated proton therapy (IMPT) versus intensity-modulated radiation therapy (IMRT) for the treatment of head and neck cancer: A dosimetric comparison.
Nguyen ML; Cantrell JN; Ahmad S; Henson C
Med Dosim; 2021 Autumn; 46(3):259-263. PubMed ID: 33648823
[TBL] [Abstract][Full Text] [Related]
44. Dosimetric feasibility of stereotactic ablative radiotherapy in pulmonary vein isolation for atrial fibrillation using intensity-modulated proton therapy.
Ren XY; He PK; Gao XS; Zhao ZL; Zhao B; Bai Y; Liu SW; Li K; Qin SB; Ma MW; Zhou J; Rong Y
J Appl Clin Med Phys; 2021 May; 22(5):79-88. PubMed ID: 33817981
[TBL] [Abstract][Full Text] [Related]
45. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
[TBL] [Abstract][Full Text] [Related]
46. Dose-Volume and Radiobiological Model-Based Comparative Evaluation of the Gastrointestinal Toxicity Risk of Photon and Proton Irradiation Plans in Localized Pancreatic Cancer Without Distant Metastasis.
Raturi VP; Tochinai T; Hojo H; Rachi T; Hotta K; Nakamura N; Zenda S; Motegi A; Ariji T; Hirano Y; Baba H; Ohyoshi H; Nakamura M; Okumura M; Bei Y; Akimoto T
Front Oncol; 2020; 10():517061. PubMed ID: 33194580
[No Abstract] [Full Text] [Related]
47. A Dosimetric Comparison of Intensity-Modulated Proton Therapy, Volumetric-Modulated Arc Therapy, and 4π Non-Coplanar Intensity-Modulated Radiation Therapy for a Patient with Parameningeal Rhabdomyosarcoma.
Chen TW; Sison J; Lee B; Olch AJ; Chang A; Giebeler A; Wong K
Cureus; 2017 Sep; 9(9):e1673. PubMed ID: 29152430
[TBL] [Abstract][Full Text] [Related]
48. Dosimetric and NTCP analyses for selecting parotid gland cancer patients for proton therapy.
Camarda AM; Vincini MG; Russo S; Comi S; Emiro F; Bazani A; Ingargiola R; Vischioni B; Vecchi C; Volpe S; Orecchia R; Jereczek-Fossa BA; Orlandi E; Alterio D
Tumori; 2024 May; ():3008916241252544. PubMed ID: 38769916
[TBL] [Abstract][Full Text] [Related]
49. Optimizing oropharyngeal cancer management by using proton beam therapy: trends of cost-effectiveness.
Li G; Xia YF; Huang YX; Okat D; Qiu B; Doyen J; Bondiau PY; Benezery K; Gao J; Qian CN
BMC Cancer; 2021 Aug; 21(1):944. PubMed ID: 34419008
[TBL] [Abstract][Full Text] [Related]
50. The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: A planning comparative study.
van der Laan HP; van de Water TA; van Herpt HE; Christianen ME; Bijl HP; Korevaar EW; Rasch CR; van 't Veld AA; van der Schaaf A; Schilstra C; Langendijk JA;
Acta Oncol; 2013 Apr; 52(3):561-9. PubMed ID: 22708528
[TBL] [Abstract][Full Text] [Related]
51. Comparison of photon volumetric modulated arc therapy, intensity-modulated proton therapy, and intensity-modulated carbon ion therapy for delivery of hypo-fractionated thoracic radiotherapy.
Chi A; Lin LC; Wen S; Yan H; Hsi WC
Radiat Oncol; 2017 Aug; 12(1):132. PubMed ID: 28810881
[TBL] [Abstract][Full Text] [Related]
52. [Not Available].
Behrends C; Haussmann J; Kramer PH; Langendijk JA; Gottschlag H; Geismar D; Budach W; Timmermann B
Z Med Phys; 2021 Feb; 31(1):5-15. PubMed ID: 33358063
[TBL] [Abstract][Full Text] [Related]
53. Impact of model and dose uncertainty on model-based selection of oropharyngeal cancer patients for proton therapy.
Bijman RG; Breedveld S; Arts T; Astreinidou E; de Jong MA; Granton PV; Petit SF; Hoogeman MS
Acta Oncol; 2017 Nov; 56(11):1444-1450. PubMed ID: 28828923
[TBL] [Abstract][Full Text] [Related]
54. Dosimetric Comparison of Helical Tomotherapy, Volumetric-Modulated Arc Therapy, and Intensity-Modulated Proton Therapy for Angiosarcoma of the Scalp.
Mizuno T; Tomita N; Takaoka T; Tomida M; Fukuma H; Tsuchiya T; Shibamoto Y
Technol Cancer Res Treat; 2021; 20():1533033820985866. PubMed ID: 33517860
[TBL] [Abstract][Full Text] [Related]
55. Intensity-modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes.
Lewis GD; Holliday EB; Kocak-Uzel E; Hernandez M; Garden AS; Rosenthal DI; Frank SJ
Head Neck; 2016 Apr; 38 Suppl 1():E1886-95. PubMed ID: 26705956
[TBL] [Abstract][Full Text] [Related]
56. Lower doses to hippocampi and other brain structures for skull-base meningiomas with intensity modulated proton therapy compared to photon therapy.
Florijn MA; Sharfo AWM; Wiggenraad RGJ; van Santvoort JPC; Petoukhova AL; Hoogeman MS; Mast ME; Dirkx MLP
Radiother Oncol; 2020 Jan; 142():147-153. PubMed ID: 31522879
[TBL] [Abstract][Full Text] [Related]
57. Normal tissue complication probability models in plan evaluation of children with brain tumors referred to proton therapy.
Stokkevåg CH; Indelicato DJ; Herfarth K; Magelssen H; Evensen ME; Ugland M; Nordberg T; Nystad TA; Hægeland C; Alsaker MD; Ulven K; Dale JE; Engeseth GM; Boer CG; Toussaint L; Kornerup JS; Pettersen HES; Brydøy M; Brandal P; Muren LP
Acta Oncol; 2019 Oct; 58(10):1416-1422. PubMed ID: 31364899
[No Abstract] [Full Text] [Related]
58. A treatment planning comparison of volumetric modulated arc therapy and proton therapy for a sample of breast cancer patients treated with post-mastectomy radiotherapy.
Hernandez M; Zhang R; Sanders M; Newhauser W
J Proton Ther; 2015; 1(1):. PubMed ID: 29104948
[TBL] [Abstract][Full Text] [Related]
59. Organ sparing potential and inter-fraction robustness of adaptive intensity modulated proton therapy for lung cancer.
van der Laan HP; Anakotta RM; Korevaar EW; Dieters M; Ubbels JF; Wijsman R; Sijtsema NM; Both S; Langendijk JA; Muijs CT; Knopf AC
Acta Oncol; 2019 Dec; 58(12):1775-1782. PubMed ID: 31556764
[No Abstract] [Full Text] [Related]
60. Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer.
Moreno AC; Frank SJ; Garden AS; Rosenthal DI; Fuller CD; Gunn GB; Reddy JP; Morrison WH; Williamson TD; Holliday EB; Phan J; Blanchard P
Oral Oncol; 2019 Jan; 88():66-74. PubMed ID: 30616799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
